慢性髓性白血病慢性期患者达沙替尼治疗后深度分子学缓解停药无治疗缓解:DASFREE研究5年最终分析
DASFREE研究纳入84例接受达沙替尼治疗≥2年且稳定深度分子学缓解的慢性髓性白血病慢性期患者,停药后随访5年,5年无治疗缓解率为44%(n=37),39个月后无复发,46例复发重启达沙替尼后中位1.9个月重获主要分子学反应,安全性与此前报告一致。
要点
- 达沙替尼停药后5年无治疗缓解率为44%(37/84)。
- 停药后39个月后无复发,复发患者重启达沙替尼中位1.9个月重获主要分子学反应。
- 停药期间最常见不良事件为关节痛(18%,15/84),9例(11%)报告15起停药事件。
核心结论
- 在持续深度分子学缓解后停用达沙替尼的患者中,近半数在5年最终随访时维持无治疗缓解。
- 所有可评估的复发患者重启达沙替尼后迅速重获深度分子学缓解,表明达沙替尼停药是可行且可能长期的选择。
- 安全性特征与此前报告一致。
研究设计与样本
- DASFREE研究(ClinicalTrials.gov;NCT01850004)为达沙替尼停药后无治疗缓解研究,本次报告5年更新。
- 纳入接受达沙替尼治疗≥2年且稳定深度分子学缓解后停药的患者,随访5年。
- 共84例患者停用达沙替尼,最短随访60个月。
主要发现
- 84例停药患者中,5年无治疗缓解率为44%(n=37)。
- 停药后39个月后无复发。
- 46例复发并重启达沙替尼的可评估患者中,中位1.9个月重获主要分子学反应。
- 停药期间最常见不良事件为关节痛(18%,15/84)。
- 9例患者(11%)共报告15起停药事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with chronic myeloid leukaemia in chronic phase (CML-CP) who have a sustained deep molecular response (DMR) are eligible to discontinue treatment and attempt treatment-free remission (TFR). In the DASFREE study (ClinicalTrials.gov; NCT01850004), the 2-year TFR rate after dasatinib discontinuation was 46%; here we present the 5-year update. Patients with a stable DMR after ≥2 years of dasatinib therapy discontinued treatment and were followed for 5 years. At a minimum follow-up of 60 months, in 84 patients discontinuing dasatinib, the 5-year TFR rate was 44% (n = 37). No relapses occurred after month 39 and all evaluable patients who relapsed and restarted dasatinib (n = 46) regained a major molecular response in a median of 1.9 months. The most common adverse event during the off-treatment period was arthralgia (18%, 15/84); a total of 15 withdrawal events were reported in nine patients (11%). At the 5-year final follow-up, almost half of the patients who discontinued dasatinib after a sustained DMR maintained TFR. All evaluable patients who experienced a relapse quickly regained a DMR after restarting dasatinib, demonstrating that dasatinib discontinuation is a viable and potentially long-term option in patients with CML-CP. The safety profile is consistent with the previous report.
引用
- Shah NP, García-Gutiérrez V, Jiménez-Velasco A, et al. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. Br J Haematol. 2023. PMID: 37246588. doi:10.1111/bjh.18883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。